NZW Stock Overview
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Molecular Templates, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.95 |
| 52 Week High | US$10.51 |
| 52 Week Low | US$3.86 |
| Beta | 1.43 |
| 1 Month Change | 0% |
| 3 Month Change | -1.67% |
| 1 Year Change | -7.54% |
| 3 Year Change | -92.84% |
| 5 Year Change | -86.82% |
| Change since IPO | -88.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| NZW | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | -1.7% |
| 1Y | -7.5% | -15.7% | 1.4% |
Return vs Industry: NZW exceeded the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: NZW underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| NZW volatility | |
|---|---|
| NZW Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NZW has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NZW's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 111 | Eric Poma | www.mtem.com |
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors.
Molecular Templates, Inc. Fundamentals Summary
| NZW fundamental statistics | |
|---|---|
| Market cap | €25.93m |
| Earnings (TTM) | -€43.67m |
| Revenue (TTM) | €47.07m |
0.6x
P/S Ratio-0.6x
P/E RatioIs NZW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NZW income statement (TTM) | |
|---|---|
| Revenue | US$50.35m |
| Cost of Revenue | US$72.02m |
| Gross Profit | -US$21.67m |
| Other Expenses | US$25.04m |
| Earnings | -US$46.71m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.69 |
| Gross Margin | -43.05% |
| Net Profit Margin | -92.78% |
| Debt/Equity Ratio | 0% |
How did NZW perform over the long term?
See historical performance and comparison